CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Capital Expenditures of $504000.0 for Q1 2026, down 2.51% sequentially from $517000.0 in Q4 2025, and up 144.66% YoY from $206000.0 in Q1 2025.
CRISPR Therapeutics AG (CRSP) Capital Expenditures (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Capital Expenditures for 12 years, with the latest figure at $504000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 144.66% year-over-year to $504000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 435.73% YoY) and the FY2025 annual result came in at $914000.0, up 493.51% from the prior year.
- Capital Expenditures retreated to $504000.0 in Q1 2026 per CRSP's latest filing, from $517000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $19.1 million in Q2 2022 and troughed at -$20.1 million in Q3 2022.
- A 5-year average of $259882.4 and a median of $206000.0 in 2025 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 179.35% in 2024, down 5232.14% in 2024.
- Over 5 years, Capital Expenditures stood at -$2.8 million in 2022, then soared by 99.0% to -$28000.0 in 2023, then plunged by 5232.14% to -$1.5 million in 2024, then jumped by 134.63% to $517000.0 in 2025, then fell by 2.51% to $504000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $504000.0, $517000.0, and $74000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 648,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 648,000.00 |
| Jun 30, 2026 | 648,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Mar 31, 2026 | 504,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Sep 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 117,000.00 |
| Mar 31, 2025 | 206,000.00 |
| Mar 31, 2025 | 206,000.00 |
| Dec 31, 2024 | -1.49 Mn |
| Dec 31, 2024 | -1.49 Mn |
| Sep 30, 2024 | 219,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Jun 30, 2024 | 707,000.00 |
| Mar 31, 2024 | 721,000.00 |
| Mar 31, 2024 | 721,000.00 |